Precision medicine

Higher tumor mutational burden is linked to improved survival across multiple cancer types.

Simultaneous multiplex immunohistochemistry can provide efficient testing of multiple targets when diagnosing and selecting treatment for cancer

A response to David Rimm’s letter that supports the role of PD-L1 testing in improving outcomes for cancer patients.

David Rimm challenges the sensitivity and reproducibility of a new assay for PD-L1 detection.

Techniques like droplet digital PCR technology can assist with early monitoring of cancer immunotherapy to ensure the right treatment for each patient

Genomic research has a diversity problem that could restrict the future effectiveness of precision medicine for minority groups

Prostate cancer prognosis presents a challenge – but a new algorithmic tool may help personalize predictions

Decentralized genomic testing in China will allow earlier breast cancer diagnosis and more personalized treatment decisions

New guidelines for CYPC29 genotyping ensure that the correct alleles are tested and patients are prescribed the correct doses of common drugs

Pathology’s great strides forward in artificial intelligence and machine learning will bring us to the forefront of personalized medicine